Results 221 to 230 of about 788,696 (364)
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti–IL‐5 therapy, treats conditions systemically, while functional endoscopic sinus surgery ...
Jens Tidemandsen +9 more
wiley +1 more source
Effect and Threshold of Endoscopic Findings for CRS Control Status and Long‐Term Outcome Prediction
ABSTRACT Background EPOS 2020 defined chronic rhinosinusitis (CRS) disease control using patient symptoms and medication usage but endoscopic findings were considered optional. The effect of adding endoscopic features, an appropriate threshold, and their association with present or future symptom control have not been studied.
Steven Chun‐Kang Liao +14 more
wiley +1 more source
Dysbiosis and Links of the Middle Ear, Nasal, and Oral Microbiota in Chronic Otitis Media with Effusion. [PDF]
Li J +8 more
europepmc +1 more source
Congenital Middle Ear Cholesteatoma [PDF]
J Walter, Kutz, Rick A, Friedman
openaire +2 more sources
INFLAMMATORY DISEASES OF THE MIDDLE EAR IN CHILDREN
Е. П. Карпова, K Yu Burlakova
openalex +2 more sources
THE MIDDLE EAR APPARATUS OF THE TUCO-TUCO CTENOMYS SOCIABILIS (RODENTIA, CTENOMYIDAE) [PDF]
Matthew J. Mason
openalex +1 more source
ABSTRACT Background Pseudomonas aeruginosa is an opportunistic pathogen in cystic fibrosis‐related chronic rhinosinusitis (CF‐CRS) that produces phenazine metabolites pyocyanin and 1‐hydroxyphenazine (1‐HP), which may have detrimental effects on mitochondria, reactive oxygen species (ROS), Ca2+ signaling, and apoptosis.
Joel C. Thompson +8 more
wiley +1 more source
Auditory Outcomes in Patients Undergoing Orthognathic Surgery: An Analysis of Middle Ear Disease. [PDF]
Hughes SE +4 more
europepmc +1 more source
ABSTRACT Background Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health‐related quality of life and posing a safety hazard. Methods WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo ...
Joaquim Mullol +14 more
wiley +1 more source

